The search for better noncholinergic treatment options for Alzheimer's disease

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 9, 2003, Pages 18-22

  Mintzer, Jacobo E ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; ARTHROTEC; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; DICLOFENAC; DIZOCILPINE; DONEPEZIL; DOPAMINE RECEPTOR; GINKGO BILOBA EXTRACT; GLUTAMATE RECEPTOR; MEMANTINE; MISOPROSTOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PERPHENAZINE; PHENCYCLIDINE; PLACEBO; RISPERIDONE; RIVASTIGMINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACRINE; TAU PROTEIN;

AGITATION; ALZHEIMER DISEASE; APATHY; CAREGIVER; CHOLINERGIC TRANSMISSION; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DELUSION; DEPRESSION; DISTRESS SYNDROME; DOPAMINERGIC TRANSMISSION; DRUG EFFICACY; HALLUCINATION; HUMAN; INFLAMMATION; INSOMNIA; MENTAL INSTABILITY; NERVOUSNESS; NEUROCHEMISTRY; OXIDATION; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC TRANSMISSION; SIDE EFFECT; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE INCONTINENCE;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIPSYCHOTIC AGENTS; DIZOCILPINE MALEATE; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MEMANTINE; PHENCYCLIDINE; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN UPTAKE INHIBITORS;

EID: 0041921073     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (17)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-1342
2. Alzheimer's Disease Fact Sheet. Alzheimer's Disease Education and Referral Site. Available at: http://www.alzheimers.org/pubs/ adfact.html#introduction. Accessed Jan. 7, 2003
3. Gingko Biloba Fact Sheet. Alzheimer's Disease Education and Referral Center Web Site. Available at: http://www.alzheimers.org/pubs/ gingko.html. Accessed Jan. 7, 2003
4. Sifton DW, ed. PDR Drug Guide for Mental Health Professionals. Montvale, NJ: Thomson Medical Economics; 2002
5. LeBars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of ginkgo. JAMA 1997;278: 1327-1332
6. Van Dongen MC, Van Rossum E, Kessels AGH, et al. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairments: new results of a randomised clinical trial. J Am Geriatr Soc 2000;48:1183-1194
7. Wettstein A. Cholinesterase inhibitors and gingko extracts: are they comparable in the treatment of dementia? comparison of published placebo-controlled efficacy studies of at least 6 months' duration. Phytomedicine 2000;6:393-401
8. Doraiswamy PM, Bieber F, Kaiser L, et al. The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997;48: 1511-1517
9. Scharf S, Mander A, Ugoni A, et al. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53:197-201
10. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999;38:735-767
11. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry 2003;64(suppl 9):7-10
12. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341
13. Tariot PN, Farlow MR, Grossberg G, et al. Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease [abstract]. J Am Geriatr Soc 2003;51(suppl 4):S225-S226
14. Lyketsos CG, Steinberg M, Tschanz JT, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000;157:708-714
15. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia. J Clin Psychiatry 1999;60:107-115
16. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities. Arch Gen Psychiatry 2000;57:968-976
17. Pollock BG, Mulsant BH, Sweet RA, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry 2002;159:460-464